Evidence map›Paper›PMID 42255656›Full record

ArticleACS omega2026

Characterization of [

Sivan Subburaju, Anna W Sromek, Philip Seeman, John L Neumeyer

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sivan SubburajuDivision of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, 115 Mill Street, Belmont, Massachusetts 02478, United States.ORCID https://orcid.org/0000-0003-3111-9859
Anna W SromekDivision of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, 115 Mill Street, Belmont, Massachusetts 02478, United States.ORCID https://orcid.org/0000-0001-9753-5797
Philip SeemanDepartments of Pharmacology and Psychiatry, University of Toronto, 260 Heath Street West, Unit 605, Toronto, Ontario, Canada M5P 3L6.
John L NeumeyerDivision of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, 115 Mill Street, Belmont, Massachusetts 02478, United States.ORCID https://orcid.org/0000-0003-2287-9864

Funding

Imaging the Functional State of the D2high Receptor in drug induced dopamine supersensitivity in schizophreniaR01MH134074 · NIMH · MCLEAN HOSPITAL · PI SIVAN SUBBURAJU · 2024 to 2026
$1.8M
Preclinical Validation of Novel High Affinity D2 Receptor Agonists for PET NeuroimagingR44OD024615 · OD · NATURAL PHARMACIA INTERNATIONAL, INC. · PI NEUMEYER, JOHN L · 2017 to 2018
$999k
Preclinical evaluation of the D2 receptor agonist MCL-524 as diagnostic marker for presymptomatic Parkinson's DiseaseR21NS131692 · NINDS · MCLEAN HOSPITAL · PI SUBBURAJU, SIVAN · 2023 to 2024
$451k
Development of a Tritiated Agonist Radioligand for the D2 ReceptorR43OD020186 · OD · NATURAL PHARMACIA INTERNATIONAL, INC. · PI NEUMEYER, JOHN L · 2014 to 2014
$148k
NIH HHS R43 OD020186NIH HHS R44 OD024615NIMH NIH HHS R01 MH134074NINDS NIH HHS R21 NS131692
6 · The paper itself

Abstract

The D

Identifiers

PMID42255656
PMCPMC13234790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.